BPC-157 in Pittsburgh: What to Know First

BPC-157 is a synthetic peptide made of 15 amino acids, studied mostly in laboratory and animal research so far. If you’re looking into it in Pittsburgh, you probably have a goal in mind, and that goal is the right place to start.

Our view at Aetheria Aesthetics & Wellness™ in Pittsburgh’s North Hills is simple. A question about BPC-157 is a good reason to sit down with a provider, in person, and talk through your goals, your health history, and what the evidence shows.

Update, November 2026

On October 30, 2026, HHS published a Federal Register notice for a draft “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” The policy covers BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. It is not an FDA approval, and BPC-157 is still not an FDA-approved medication. It’s a draft that HHS says it may revisit, and FDA may later propose adding some or all of these peptides to the 503A bulks list through rulemaking.

We keep up with FDA guidance on peptides and revisit our approach whenever it’s updated. If you have questions about BPC-157, the best next step is an in-person consultation with Melissa Kolowitz, PA-C.

What BPC-157 is

BPC stands for body protection compound, a larger protein that researchers found in human gastric juice. BPC-157 is a 15-amino-acid fragment of it, first described by Sikirić and colleagues in 1993. In research papers it often appears under a code instead, most commonly PL 14736, so a search for either name can turn up the same studies.

A peptide is a short chain of amino acids, the same building blocks that make up proteins. Your body makes many of its own. “Peptide” describes a structure, not an effect, so two peptides can have little in common beyond the label, and each one deserves its own look.

Where the research stands

Most published research on BPC-157 comes from laboratory and animal studies, largely in rats and mice. Published research in people is limited so far.

A 2025 systematic review in HSS Journal puts numbers on that. Of the 36 studies it included, 35 were preclinical, meaning lab or animal work, and one was a clinical study in people. For what researchers have reported on safety, the review itself is the place to read it.

BPC-157 is not an FDA-approved medication.

Animal research, a small study in people, and solid evidence for your own concern are different things. Knowing which one you’re reading helps you ask sharper questions.

Our thoughts on BPC-157

BPC-157 is getting a lot of attention, and we’re paying attention too. We follow the research as it develops and keep up with FDA guidance on peptides, so our approach stays current.

Whether BPC-157 or any peptide makes sense for you depends on you: your goals, your history, your medications, and your labs. That’s why a good next step is a conversation with a provider who will assess your situation in person and talk through your options.

Bring your goal to the conversation

You can come to a consultation curious about BPC-157 without having decided anything. The question you’ve been carrying around is a fine place to begin.

From there, the useful questions are about you. What are you hoping to feel or do differently? When did it start? What have you already tried, and what helped? A provider learns more from that story than from the name of a compound.

Your provider will also want the wider picture: existing diagnoses, medications, supplements, and any care you’re already receiving. Sleep, nutrition, activity, and the demands of your day can matter too. Testing should have a purpose. Bring the lab results you already have, and your provider can talk through whether anything new would answer a specific question.

What to bring and what to ask

• Describe your goal. What activity, symptom, or part of daily life prompted your interest?
• Bring your history. Include current diagnoses, past treatment, relevant records, and existing lab results.
• List what you take. Include prescription medications, over-the-counter products, and supplements, with doses.
• Share relevant circumstances. Mention upcoming procedures, pregnancy, breastfeeding, or plans to conceive.
• Ask about the reasoning. What does the evidence show for your concern, what alternatives are there, and what would follow-up look like?

If you compete in a tested sport, raise that too. The 2026 WADA Prohibited List names BPC-157 under S0, prohibited in and out of competition. The anti-doping organization that governs your sport is the authority on what’s allowed.

BPC-157 questions in Pittsburgh’s North Hills

Every program at Aetheria starts with an in-person consultation with Melissa Kolowitz, PA-C. We serve patients across the North Hills, Allegheny County, and surrounding areas, from our studio at Ross Park Mall. Many come from Ross Township, Wexford, Cranberry Township, Sewickley, and Mars.

Melissa is the provider you see at every visit, so follow-up starts from what you’ve already talked through: what you were experiencing, what you discussed, and what’s happened since. Your questions about BPC-157 can be part of that first conversation.

Learn about peptide therapy at Aetheria or book a consultation with Melissa Kolowitz, PA-C, in Pittsburgh’s North Hills.

BPC-157 quick facts

• What it is: a synthetic peptide, 15 amino acids long
• Name: BPC stands for body protection compound
• First described: 1993
• Other names in research papers: PL 14736
• Research so far: mostly laboratory and animal studies
• FDA status: not an FDA-approved medication
• In sport: named on the 2026 WADA Prohibited List

Sources

• Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, October 30, 2026

Research and regulatory references checked November 5, 2026. This page is educational and does not constitute medical advice.